Profile data is unavailable for this security.
About the company
Adcock Ingram Holdings Limited is a South Africa-based healthcare company. The Company’s segments include Consumer, Over the Counter (OTC), Prescription, Hospital, and Other. The Consumer segment is engaged mainly in the fast-moving consumer goods (FMCG) space. Its OTC segment focuses on brands sold predominantly in pharmacies. Its Prescription segment markets products prescribed by medical practitioners, and specialized instruments and surgical products. Its Hospital segment supplies hospital and critical care products, including intravenous solutions, blood collection products and renal dialysis systems. Its Other segment include shared services and other support services, including regulatory services in India, as well as the investment in the joint venture and cash and bank overdraft balances which are managed on a central basis in Southern Africa.
- Revenue in ZAR (TTM)9.64bn
- Net income in ZAR814.01m
- Incorporated2007
- Employees2.44k
- LocationAdcock Ingram Holdings Ltd1 New Road, (c/o New Road & 7th Street)MIDRAND 1682South AfricaZAF
- Phone+27 116350000
- Fax+27 865530000
- Websitehttps://www.adcock.co.za/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SeQuent Scientific Ltd | 3.11bn | 35.40m | 10.44bn | 1.20k | 298.29 | 7.16 | 52.48 | 3.35 | 0.6537 | 0.6537 | 57.25 | 27.23 | 0.9464 | 2.28 | 4.46 | 12,129,000.00 | 1.79 | 1.09 | 2.94 | 1.76 | 45.86 | 41.97 | 1.89 | 1.18 | 0.9564 | 1.26 | 0.3974 | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
Shandong Boan Biotechnology Co Ltd | 1.80bn | 154.74m | 10.73bn | 777.00 | 65.90 | 2.93 | 32.68 | 5.95 | 0.1305 | 0.1305 | 1.52 | 2.94 | 0.3069 | 1.10 | 2.60 | 952,026.10 | 2.63 | -- | 3.43 | -- | 74.10 | -- | 8.59 | -- | 1.03 | 4.01 | 0.3369 | -- | 19.80 | -- | 64.02 | -- | -- | -- |
Chengdu Olymvax Biopharmaceuticals Inc | 1.33bn | -21.77m | 10.78bn | 471.00 | -- | 4.73 | -- | 8.13 | -0.0219 | -0.0219 | 1.31 | 2.24 | 0.3301 | 0.3685 | 1.04 | 1,126,255.00 | -0.9143 | 3.17 | -1.28 | 4.68 | 94.19 | 93.00 | -2.77 | 7.44 | 1.67 | -0.5392 | 0.2915 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
Phathom Pharmaceuticals Inc | 476.11m | -6.15bn | 10.82bn | 452.00 | -- | -- | -- | 22.72 | -5.69 | -5.69 | 0.4398 | -2.74 | 0.0842 | 2.68 | -- | 58,119.47 | -108.79 | -83.26 | -126.95 | -93.77 | 83.54 | -- | -1,292.14 | -135,982.00 | 5.68 | -5.60 | 1.56 | -- | -- | -- | -1.96 | -- | -- | -- |
Adcock Ingram Holdings Limited | 9.64bn | 814.01m | 10.86bn | 2.44k | 12.80 | 1.64 | -- | 1.13 | 5.26 | 5.26 | 62.36 | 40.94 | 1.16 | 2.57 | 4.50 | 3,958,591.00 | 9.80 | 10.24 | 13.97 | 14.44 | 33.38 | 30.34 | 8.44 | 9.05 | 0.9267 | -- | 0.0493 | 41.41 | 5.60 | 6.38 | -9.39 | 3.37 | -9.93 | 6.58 |
Tibet Weixinkang Pharmaceutical Co Ltd | 3.14bn | 617.90m | 10.96bn | 701.00 | 17.74 | 2.96 | -- | 3.49 | 0.5677 | 0.5677 | 2.89 | 3.41 | 0.6778 | 16.41 | 5.56 | 1,791,483.00 | 13.33 | 8.20 | 17.01 | 11.13 | 53.45 | 50.20 | 19.67 | 11.53 | 3.27 | -- | 0.0075 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
Lionco Pharmaceutical Group Co Ltd | 693.32m | -254.63m | 10.99bn | 475.00 | -- | 5.13 | -- | 15.85 | -0.144 | -0.144 | 0.3828 | 1.19 | 0.1843 | 2.48 | 4.41 | 583,571.30 | -6.77 | 0.7396 | -7.85 | 0.9562 | 41.77 | 80.88 | -36.73 | 2.08 | 4.94 | -4.74 | 0.2409 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 1.79bn | 584.75m | 11.04bn | 1.14k | 18.67 | 1.98 | -- | 6.19 | 1.19 | 1.19 | 3.63 | 11.26 | 0.2367 | 0.7194 | 7.25 | 624,455.80 | 7.75 | 10.04 | 9.09 | 11.63 | 80.01 | 83.66 | 32.75 | 28.29 | 3.48 | -- | 0.2098 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
Kyorin Pharmaceutical Co Ltd | 13.96bn | 561.54m | 11.05bn | 2.04k | 17.50 | 0.6482 | 10.26 | 0.7916 | 83.83 | 83.83 | 2,084.19 | 2,263.35 | 0.6745 | 1.21 | 3.18 | 58,635,650.00 | 2.71 | 3.05 | 3.36 | 3.79 | 42.87 | 47.11 | 4.02 | 4.76 | 1.74 | -- | 0.1593 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
Eyepoint Pharmaceuticals Inc | 828.48m | -1.88bn | 11.05bn | 121.00 | -- | 2.19 | -- | 13.34 | -2.01 | -2.01 | 0.9018 | 4.09 | 0.1983 | 1.05 | 106.19 | 377,793.40 | -44.94 | -40.44 | -59.48 | -47.79 | 91.48 | 83.45 | -226.57 | -186.23 | 5.45 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Public Investment Corporation (SOC) Ltd.as of 30 Jun 2023 | 15.34m | 9.04% |
Old Mutual Customised Solutions (Pty) Ltd.as of 30 Jun 2024 | 1.22m | 0.72% |
Dimensional Fund Advisors LPas of 07 Nov 2024 | 1.17m | 0.69% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 909.72k | 0.54% |
Abax Investments (Pty) Ltd.as of 30 Sep 2024 | 840.00k | 0.50% |
ClucasGray Investment Management (Pty) Ltd.as of 29 Mar 2024 | 820.08k | 0.48% |
Merchant West Investments (Pty) Ltd.as of 30 Aug 2024 | 603.38k | 0.36% |
Centaur Asset Management Pty Ltd.as of 30 Sep 2024 | 567.79k | 0.34% |
Camissa Asset Management Pty Ltd.as of 31 Mar 2024 | 376.04k | 0.22% |
Bateleur Capital (Pty) Ltd.as of 31 Mar 2024 | 335.88k | 0.20% |